Target Attainment of TDM-guided Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients

Overview

Although alternative dosing strategies can improve antimicrobial exposure in critically ill patients, the high PK variability in this population means that some may still receive sub-optimal antibiotic exposure leading to unfavourable clinical outcomes. Therapeutic drug management (TDM) guided dosing is the only safe and effective way to ensure that all critically ill patients achieve therapeutic antimicrobial exposures and to minimise the likelihood of toxicity. For experts, TDM should be a standard of care, in particular for β-lactams. Nevertheless, because of the assay method for β-lactams and the need for bioanalytical experts, delays in obtaining results frequently occurred. These barriers, combined with difficulties in the interpretation of TDM results, need to be addressed in order to increase its routine utilization. Consequently, study aiming at identify which subgroup of patients or infection are more likely to benefit from TDM are urgently warranted This prospective observational study aimed at evaluating target attainment of piperacillin/tazobactam (PIP/TAZ) and cefepim (CEF) with the use of a Therapeutic Drug Monitoring (TDM) in critically patients during the routine care

Full Title of Study: “Target Attainment of TDM-guided Continuous Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients: a Prospective Observational Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 1, 2019

Interventions

  • Other: dosage of concentration of piperacillin and cefepim
    • Dosage of total plasma concentration of piperacillin and cefepim at different timepoints

Arms, Groups and Cohorts

  • critically ill patients
    • Critically ill patients receiving continuous infusion of piperacillin/tazbactam or cefepim and dosage of plasma concentration of the B lactam administered

Clinical Trial Outcome Measures

Primary Measures

  • to determine the percentage of patients who met the PK/PD targets at 24 hours
    • Time Frame: Day 1
    • PK/PD target was defined as follows: Concentration of piperacillin or cefepim between a lower and a upper limit: The lower limit was defined as estimated free concentration above 4 times the epidemiological cut-off value of suspected bacteria The upper limit was based on known limit of neurotoxicity, namely 35 and 160 mg/L for cefepim and piperacillin, respectively Consequently : for piperacillin : the PK/PD target is considered to be reach if the free concentration of PIPERACILLIN/TAZOBACTAM is between 32 and 160 mg/l for cefepim : the PK/PD target is considered to be reach if the free concentration of CEFEPIM is between 4 and 35 mg/l

Secondary Measures

  • to determine the percentage of patients who met the PK/PD targets “exposure” at 24 hours
    • Time Frame: Day 1
    • PK/PD target “exposure” take into account only the the lower limit was defined as estimated free concentration above 4 times the epidemiological cut-off value of suspected bacteria Consequently : for piperacillin : the PK/PD target is considered to be reach if the free concentration of PIPERACILLIN/TAZOBACTAM is above 32 mg/l for cefepim : the PK/PD target is considered to be reach if the free concentration of CEFEPIM is above 4 mg/l
  • factors associated with target attainment at day 1
    • Time Frame: Statistical analysis after 2 years of inclusion
    • effect of age on antibiotic concentration
  • factors associated with target attainment at day 1
    • Time Frame: Statistical analysis after 2 years of inclusion
    • effect of renal clearance on antibiotic concentration
  • factors associated with target attainment at day 1
    • Time Frame: Statistical analysis after 2 years of inclusion
    • effect of presence of septic shock on antibiotic concentration
  • factors associated with dose changing
    • Time Frame: Statistical analysis after 2 years of inclusion
    • effect of presence of septic shock on number of dose changing after analyse of antibiotic concentration
  • factors associated with dose changing
    • Time Frame: Statistical analysis after 2 years of inclusion
    • effect of renal clearance on number of dose changing after analyse of antibiotic concentration

Participating in This Clinical Trial

Inclusion Criteria

  • Minimun age limits 18 years – Critically ill patient receiving piperacillin or cefepim administered continuously Exclusion Criteria:

  • Beta lactam allergy – Pregnancy – Age less than 18 years

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Central Hospital, Nancy, France
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Emmanuel NOVY, Principal Investigator, Central Hospital, Nancy, France

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.